A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease

The purpose of this study is to investigate the safety and efficacy of BEY2153 in patients with early Alzheimer's Disease. Subjects who meet the inclusion and exclusion criteria will be randomized 1:1:1 to one of three treatment arms for 26 weeks administration. The extension study for additional 26 weeks will be conducted open-label with one treatment arm. Subjects will take BEY2153 orally once a day during the study.

NCT Number	NCT06885567
Lead Sponsor	BeyondBio Inc.
Conditions	Alzheimer Disease, Alzheimer' Disease
Enrollment	90 participants
Start Date	2025-07
Primary Completion	2028-07 (estimated)
Study Completion	2028-08 (estimated)
Updated on ClinicalTrials.gov	2025-03-20